Abstract
Choline kinase (ChoK) and its product, phosphocholine (PCho), have been implicated in human carcinogenesis. Inhibition of this enzyme has been shown to be an efficient antitumor strategy in vivo. The aim of this study was to assess the relationship between the regulation of ChoK and clinical features in patients with breast cancer. To that end, normal and tumoral tissues from 53 patients with breast carcinomas were analysed for ChoK activity and expression, and compared to some clinical parameters. We report a relevant increase in ChoK activity in 38.5% of the tumoral tissues analysed when compared to the normal levels in healthy tissues. Furthermore, some clinical features were found significant versus ChoK status. First, an association of choline enzymatic activity with histological tumor grade was observed (P<0.001). In addition, increased ChoK activity was also associated with ER-negative breast carcinomas (P=0.037). A significant association between ChoK overexpression and both high histologic tumor grade (P=0.017) and ER-negative tumors (P=0.003) was found. Finally, ChoK overexpression was found in 17% of the samples and all corresponded with those that display the highest increase in ChoK activity (P<0.001). Here we provide evidence that ChoK may be related to the development of human breast cancer, suggesting that this finding may constitute the basis for the development of a novel antitumoral strategy for these patients.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Bonilla Velasco F, España Saz P, Provencio Pulla M . 2001 Rev. Oncología 3: 130–136
Dominguez G, Silva J, Silva JM, Garcia JM, Miralles C, Rodríguez O, Jareño E, Provencio M, España P, Bonilla F . 2000 Breast Cancer Res. Treat. 63: 17–22
Fentiman IS . 2000 Eur. J. Cancer 36: 1085–1088
Ferlay J, Bray F, Pisani P, Parkin DM . 2001 Cancer Incidence, Mortality and Prevalence Worldwide IARC CancerBase No. 5 Lyon: IARC Press
Hernández-Alcoceba R, Fernández F, Lacal JC . 1999 Cancer Res. 59: 3112–3118
Hernández-Alcoceba R, Saniger L, Campos J, Nunez MC, Khaless F, Gallo MA, Espinosa A, Lacal JC . 1997 Oncogene 15: 2289–2301
Kumar R, Mandal M, Vadlamudi R . 2000 Semin. Oncol. 27: Suppl 11 84–91
Lacal JC . 2001 Idrugs 4: 419–426
McNeil BJ, Hanley JA . 1984 Med. Decis. Making 2: 137–150
Olopade OI, Adeyanju MO, Safa AR, Hagos F, Mick R, Thompson CB, Recant WM . 1997 Cancer J. Sci. Am. 3: 230–237
Osborne CK . 1998 N. Engl. J. Med. 339: 1609–1618
Pegram M, Hsu S, Lewis G, Peitras R, Beryt M, Sliwkowski M, Coombs D, Baly D, Kabbinavar F, Slamon D . 1999 Oncogene 18: 2241–2251
Powles T, Eeles R, Ashley S, Easton D, Chang J, Dowsett M, Tidy A, Viggers J, Davey J . 1998 Lancet 352: 98–101
Ramírez De Molina A, Penalva V, Lucas L, Lacal JC . 2002 Oncogene 21: 937–946
Salazar JM, González JF, Albanell J, Baselga J . 2001 Rev. Oncología 3: 171–179
Schneider J, Lucas R, Sanchez J, Ruibal A, Tejerina A, Martin M . 2000 Anticancer Res. 20: 4373–4377
Sluyser M . 1990 Anticancer Drugs 1: 127–132
Smith TAD, Bush C, Jameson C, Titley JC, Leach MO, Wilman DEV, McCready VR . 1993 NMR Biomed. 6: 318–323
Thor AD, Moore II DH, Edgerton SM, Kawasaki ES, Reihsaus E, Lynch HT, Marcus JN, Schwartz L, Chen LC, Mayall BH, Smith HS . 1992 J. Natl. Cancer Inst. 84: 845–855
Tripathy D, Benz CC . 1992 Cancer Treat. Res. 63: 15–60
Acknowledgements
We gratefully thank Dr S Yamashita for kindly providing us with the cDNA encoding mammalian ChoK. This work was supported by Grant 2FD1997-1569 from CICYT, Grant 99/0817 from FIS, Grant 08.1/0045.1/98 from Consejería de Educación of Comunidad de Madrid, and a special Grant from Roche Diagnostics GmbH, Pharma Research Penzberg (Alemania). We appreciate the critical reading of the manuscript by Miguel Martin and Ramón Colomer. A. Ramirez de Molina is a fellow from Fondo de Investigación Sanitaria (Instituto de Salud Carlos III), grant BEFI 99/9125 (Ref. CPC/CLC).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ramírez de Molina, A., Gutiérrez, R., Ramos, M. et al. Increased choline kinase activity in human breast carcinomas: clinical evidence for a potential novel antitumor strategy. Oncogene 21, 4317–4322 (2002). https://doi.org/10.1038/sj.onc.1205556
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1205556
Keywords
This article is cited by
-
Implantable theranostic device for in vivo real-time NMR evaluation of drug impact in brain tumors
Scientific Reports (2024)
-
Correlation between choline kinase alpha expression and 11C-choline accumulation in breast cancer using positron emission tomography/computed tomography: a retrospective study
Scientific Reports (2023)
-
Myricetin ameliorates the IL-21-induced tumorigenic phenotype of adjuvant-induced arthritis FLS by modulating the choline kinase signaling cascade
In Vitro Cellular & Developmental Biology - Animal (2023)
-
Prospective validation of 18F-Fluoroethylcholine as a tracer in PET/MRI for the evaluation of breast lesions and prediction of lymph node status
La radiologia medica (2023)
-
Inhibiting the glycerophosphodiesterase EDI3 in ER-HER2+ breast cancer cells resistant to HER2-targeted therapy reduces viability and tumour growth
Journal of Experimental & Clinical Cancer Research (2023)